title: Which donor or graft source should you choose for the strongest GVL? Is there really any difference.
abstract: Patients undergoing allogeneic hematopoietic cell transplantation (HCT) face relapse of their malignancy as the most frequent cause of treatment failure. It has been postulated that the allogeneic neoplastic potency of different donor or graft sources may differ and in some situations, a particular graft source might be preferred. Data on this supposition has been reviewed here to consider HLA-matched siblings, HLA-matched or partially matched unrelated donors (URD), unrelated umbilical cord blood (UCB), and haploidentical as well as blood or marrow grafts.
authors.affiliation: Adult Blood and Marrow Transplant Program, University of Minnesota, USA. Electronic address: weisd001@umn.edu.
authors.forename: Daniel
authors.initials: D
authors.lastname: Weisdorf
mesh_terms: D016026:Bone Marrow Transplantation; D036101:Cord Blood Stem Cell Transplantation; D006086:Graft vs Host Disease / Q000276:immunology / Q000473:pathology / Q000517:prevention & control*; D020544:Graft vs Leukemia Effect; D006680:HLA Antigens / Q000276:immunology; D006239:Haplotypes / Q000276:immunology; D018380:Hematopoietic Stem Cell Transplantation; D006650:Histocompatibility Testing; D006801:Humans; D007938:Leukemia / Q000276:immunology / Q000473:pathology / Q000628:therapy*; D012008:Recurrence; D035781:Siblings; D014184:Transplantation, Homologous; D061349:Unrelated Donors
chemical_list: D006680:HLA Antigens
keywords: GVL, graft-versus-leukemia; HCT, hematopoietic cell transplantation; HLA-matched donors; UCB, umbilical cord blood; bone marrow; graft source; haploidentical; peripheral blood; relapse